当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2017年第16期
编号:13083066
透析患者营养不良的治疗研究进展(5)
http://www.100md.com 2017年10月8日 《中国医药导报》 2017年第16期
     [25] Hung AM,Ellis CD,Shintani A,et al. IL-1 beta receptor antagonist reduces inflammation in hemodialysis patients [J]. J Am Soc Nephrol,2011,22(3):437-442.

    [26] Palmer SC,Hayen A,Macaskill P,et al. Serum levels of phosphorus,parathyroid hormone,and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease:a systematic review and meta-analysis [J]. JAMA,2011,305(11):1119-1127.

    [27] Lertdumrongluk P,Rhee CM,Park J,et al. Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients [J]. J Ren Nutr,2013, 23(6):411-421.

    [28] Streja E,Lau WL,Goldstein L,et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients [J]. Kidney Int Suppl,2013,3(5):462-468.

    [29] Yamada S,Tokumoto M,Tatsumoto N,et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia [J]. Am J Physiol Renal Physiol,2014,306(12):1418-1428.

    (收稿日期:2017-02-24 本文編辑:李亚聪), 百拇医药(刘杨艳 熊明霞 杨俊伟)
上一页1 2 3 4 5